Damir Gugić

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 589 citations

Medicine, Oncology, Pharmacology +15

Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients

Joseph Gligorov, Beyhan Ataseven, Mark Verrill et al. · European Journal of Cancer · 2017 · 46 citations · Full text

Medicine, Oncology, Pharmacology +17

Prognostic role of Nectin-4 expression in luminal B (HER2 negative) breast cancer

Jasmina Rajc, Damir Gugić, Irena Fröhlich et al. · Pathology - Research and Practice · 2017 · 32 citations

Medicine, Oncology, Pathology +16

Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors

Lidija Bošković, Maja Gašparić, Marija Petković et al. · The Breast · 2016 · 15 citations · Full text

Medicine, Endocrinology, Oncology +17